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Abstract
Background: miRNAs, endogenous oligonucleotide RNAs, play an important role in mammary gland
carcinogenesis and tumor progression. Detection of their expression and investigation of their functions could lead
to discovery of novel biomarkers for breast cancer.
Methods: In situ hybridization was used to detect miR-133a expression in formalin-fixed paraffin-embedded breast
surgical specimens from 26 benign, 34 pericancerously normal and 90 cancerous tissues. qRT-PCR was performed
to assess miR-133a levels in 6 breast cell lines and 10 benign and 18 cancerous fresh breast tissue specimens. Cell
viability, migration, and invasion assays were used to determine the role of miR-133a in regulation of breast cancer
cell growth, migration, and invasion, respectively. Luciferase assay was performed to assess miR-133a binding to
FSCN1 gene.
Results: Expression of miR-133a was reduced from normal through benign to cancerous breast tissues. Expression
of miR-133a was also low in breast cancer cell lines. The reduced miR-133a expression was associated with lymph
nodes metastasis, high clinical stages, and shorter relapse-free survivals of patients with breast cancer. Furthermore,
transfection of miR-133a oligonucleotides slightly inhibited growth but significantly decreased migration and
invasion capacity of breast cancer cells, compared with negative controls, whereas knockdown of miR-133a
expression induced breast cancer cell migration and invasion. In addition, we identified a putative miR-133a
binding site in the 3’-untranslated region (UTR) of Fascin1 (FSCN1) gene using an online bioinformatical tool. We
found that miR-133a transfection significantly reduced expression of FSCN1 mRNA and protein. The luciferase
reporter assay confirmed that FSCN1 was the direct target gene of miR-133a.
Conclusions: miR-133a expression was lost in breast cancer tissues, loss of which was associated with lymph
nodes metastasis, high clinical stages and shorter relapse-free survivals of patients with breast cancer. Functionally,
miR-133a can suppress tumor cell invasion and migration and targeted the expression of FSCN1. Future study will
verify whether detection of miR-133a expression can served as a novel biomarker for breast cancer progression and
patient prognosis.
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MicroRNAs (miRNAs) are a class of small, non-coding
RNAs of 18-24 nucleotides in length and function as
negative regulators of gene expression through inhibi-
tion of target mRNA translation or degradation of target
mRNA [1]. Through silence of their targeting mRNAs,
miRNAs play key roles in a wide variety of biological
processes, including control of embryo development [2],
cell growth [3], differentiation [4] and apoptosis [5-7].
Thus, aberrant expression of miRNAs has been impli-
cated in human carcinogenesis and cancer progression
[8-12], indicating that some miRNAs can function as
tumor suppressor genes or oncogenes. For example, up-
regulation of several miRNAs in breast cancer cells
(such as miR-9 and miR-10b) could increase tumor cell
invasion and metastasis [13,14], whereas expression of
miR-335 and miR-31 could inhibit breast cancer cell
invasion and metastasis [15,16].
Breast cancer is the most frequently diagnosed cancer
and the leading cause of cancer death for females world-
wide and in the United States, accounting for 23% of the
total cancer cases and 14% of the cancer deaths in the
world [17]. Tumor invasion and metastasis are responsi-
ble for most of cancer-related mortality [18]. However,
the mechanisms by which the factors mediate tumor
metastasis are still incompletely understood, though one
of these requirements is known to be the enhanced cell
motility. Previous studies demonstrated that certain
miRNAs (such as miR-340) were able to alter tumor cell
motility [10] through regulation of c-Met gene expres-
sions. Indeed, multiple cellular and extracellular factors
can regulate cell motility by changing the actin expres-
sion or activity. In this regards, FSCN1, an actin-bund-
ling protein, is one of the key molecules in diverse
forms of actin-based motility-structures [19]. FSCN1 is
normally expressed in mesenchymal, neuronal, and
endothelial cells but usually not expressed in normal
epithelia cells [20,21]. However, previous studies showed
that FSCN1 is highly expressed in different cancer tis-
sues or cells, such as cancers of as the mammary glands
[22], colon [23], stomach [24], ovary [25], esophagus
[26], and lung [27]. In our previous study, we screened
expression of different miRNAs in archived formalin-
fixed and paraffin-embedded breast tissue specimens by
in situ hybridization [10,28], we found significant down-
regulated miR-133a expression in breast cancer com-
pared to benign breast disease and miR-133a
downregulation was associated with disease progression.
Therefore, in this study, we first confirmed the expres-
sion of miR-133a in fresh breast tissue specimens and
breast cell lines by using qRT-PCR. After that, we
assessed the role of miR-133a in breast cancer cell lines
and then linked miR-133a expression with FSCN1
alteration.
Methods
Breast tissue specimens
There are two cohorts of clinical specimens included in
current study. For in situ hybridization assay, the tissue
specimens were obtained from 90 female patients with
breast cancer and 26 female patients with breast benign
diseases while these patients underwent surgical treat-
ment at the First Affiliated Hospital of Anhui Medical
University from March 31 2001 to April 1 2002. For
qRT-PCR assay, 18 breast cancer and 10 breast benign
diseases specimens were collected from our department
of Pathology between January to May 2010. These tissue
specimens were placed in a cryovial, snap-frozen and
stored in liquid nitrogen immediately after operation
until use. The pathohistological diagnosis of the patients
was according to breast tumor classification criteria of
World Health Organization [29]. Histology grade was
based on the Scarff-Bloom-Richardson system [30]. The
median follow-up time for the breast cancer patients
was 60 months and ranged from 8 to 64 months. The
protocol for use of patient samples in this study was
approved by our institutional review board and the
informed consent form was signed by each patient or
their guardians.
Construction of tissue microarray
The formalin-fixed and paraffin-embedded tissue blocks
were retrieved from the archives of the Department of
Pathology, the First Affiliated Hospital of Anhui Medical
University, Hefei, China. The hematoxylin and eosin-
stained tissue sections were reviewed by 2 pathologists
to identify the representative regions for tissue microar-
ray construction. After that, the area of interest in the
donor blocks was cored thrice with a 1 mm diameter
cylinder using a tissue microarrayer (Hengtai Instru-
ments, Liaoning, China), and transferred to the recipient
paraffin block. A total of three tissue microarray blocks
were constructed and sectioned for in situ hybridization
analysis of miRNA expression.
In situ hybridization
In situ hybridization to detect miR-133a expression in
breast carcinoma and benign disease tissues was per-
formed as described previously [10,28]. Briefly, tissue
microarray sections with 3 μmi nt h i c k n e s sw e r e
deparaffinized, rehydrated, and digested and then
refixed in 4% paraformaldehyde. After that, the sec-
tions were prehybridized with 150 μl of hybridization
solution and then incubated with a digoxigenin-labeled
LNA probe (Exiqon, Copenhagen, Denmark) for miR-
133a, U6 (positive control), and scrambled RNA (nega-
tive control) at 68°C for 20 h. In the next day, the sec-
tions were washed with 2× SSC, 1× SSC and 0.5× SSC
and then incubated with a mouse antidigoxin antibody
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For visualizing the positive signal, the sections were
incubated in 3,3’-diaminobenzidine solution and coun-
terstained with hematoxylin. The expression of miR-
133a was reviewed and scored independently by 2
pathologists. The staining was scored as negative, if ≤
10% of epithelial cells stained positively, whereas the
staining was scored positively if > 10% of epithelial
cells stained positively [31].
Cell lines and culture
Human breast cancer ZR75-1, SKBR3, T47D, MCF-7
and MDA-MB-231 cell lines and the nontumourigenic
HMEC cell line were obtained from the American Type
Culture Collection (Rockville, MD). ZR75-1, SKBR3 and
T47D cells were grown in Dulbecco modified Eagle
medium (DMEM, Invitrogen, Carlsbad, CA), MCF-7
cells were cultured in RPMI-1640 (Invitrogen), MDA-
MB-231 cells were cultured in Leibovitz’sL - 1 5( I n v i t r o -
gen) and HMEC cells were grown in Medium 171 with
mammary epithelial growth supplement (Cascade Biolo-
gics) supplemented with 10% fetal bovine serum
(Hyclone, Logan, UT) and incubated at 37°C in a humi-
dified incubator containing 5% CO2.
Quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
To detect miR-133a expression, RNA from cell lines and
fresh tissue samples was extracted using the mirVana
miRNA Isolation Kit (Ambion, Austin, TX) according to
the manufacturer’s instructions and then reversely tran-
scribed into cDNA using SuperScript III reverse tran-
scriptase (Invitrogen). After that, qPCR was performed
using TaqMan MicroRNA Assay kits (Applied Biosys-
tems, Foster City, CA) according to the manufacturer’s
instructions with a Stratagene M × 3000P Real Time
PCR machine (Agilent Technologies). The PCR amplifi-
cation consisted of 40 cycles (95°C for 5 s, 60°C for 20
s) after an initial denaturation at 95°C for 10 s. U6 small
nuclear RNA was used as an internal control. The
threshold cycle (Ct) is defined as the fractional cycle
number at which the fluorescence passes the fixed
threshold. The fold change of miRNA expression was
calculated using the 2
-ΔΔCt method after normalization
to U6 expression. All experiments were performed in
triplicate. In addition, relative expression levels of
FSCN1 mRNA were assessed by using SYBR Premix Ex
Taq (Perfect Real Time) kit (TaKaRa, Dalian, China)
and normalized to GAPDH mRNA. The primers for
FSCN1 were 5’-CTCATCAACCGCCCCATCAT-3’ (for-
ward) and 5’-CTGCCCACCGTCCAGTATTT-3’
(reverse) and GAPDH primers were 5’-TGCACCAC-
CAACTGCTTAGC-3’ (forward) and 5’-GGCATG-
GACTGTGGTCATGAG-3’ (reverse).
Transient miRNA and siRNA transfection
MCF-7 and MDA-MB-231 cells were selected for miR-
133a transfection. Briefly, the cells were grown overnight
and then transfected with either miR-133a mimic (Gene-
Pharma, Shanghai, China), 2’-O methylated single-
stranded miR-133a antisense oligonucleotide (ASO, Gen-
ePharma), or negative control miRNA (GenePharma)
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. The miR-133a mimic contained
synthetic small duplex sequences of miR-133a RNA that
was able to be bioprocessed into the mature miR-133a in
the cells. The sequences of negative control and ASO
negative control (GenePharma) were nonhomologous to
any human genome sequences, and used to eliminate the
potential nonsequence-specific effects. The sequences of
miR-133a mimic were: 5’-UUUGGUCCCCUUCAAC-
CAGCUG-3’ (sense), 5’-GCUGGUUGAAGGGGAC-
CAAAUU-3’ (antisense); miR-133a ASO, 5’-CAGCU-
GGUUGAAGGGGACCAAA-3’;N C ,5 ’-UUCUCC-
GAACGUGUCACGUTT-3’ (sense) and 5’-ACGUGA-
CACGUUCGGAGAATT-3’ (antisense); ASO NC, 5’-
CAGUACUUUUGUGUAGUACAA-3’. In addition,
FSCN1 siRNA or control scrambled siRNA (both from
Qiagen, Valencia, CA) was transfected into MCF-7 cells
that were transfected with or without miR-133a ASO
transfection. The target sequence of FSCN1 siRNA was
AGCCCTGGGCGTGTAGTGTAA. The efficiency of
RNA transfection was confirmed by real-time PCR
analysis.
Cell proliferation assay
Thirty-six hours after transient transfection, MCF-7 were
harvested and sub-cultured in 96-well plates for up to 96
h. After that, cell proliferation was assessed using the Cell-
Titer 96 AQueous MTS assay (Promega, Madison, WI)
according to the manufacturer’s instructions. Briefly, the
MTS reagent (20 μl) was added to each well and incubated
at 37°C for 2 h. Then, the absorbance at 492 nm was mea-
sured by using a microtiter plate reader (Bio-Rad, CA).
The experiments were in triplicate and repeated thrice.
The data were summarized as mean ± SD.
Wound healing assay
MCF-7 cells were seeded into 6-well plates and trans-
fected with either miR-133a ASO or ASO NC, and
then the cells were allowed to grow until 100% con-
fluency. Next, the cell layer was gently scratched
through the central axis using a sterile plastic tip and
loose cells were washed away. The wound healing was
observed and photographed at three preselected time
points (0, 24, and 48 h) in three random selected
microscopic fields for each condition and time point.
Sextuple assays were performed for each experiment
and repeated once.
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Tumor cell migration and invasion were carried out
using a Transwell insert (8 μm, Corning, NY). MCF-7
and MDA-MB-231 cells were first transfected with miR-
133a mimic or ASO or control RNA. 48 h later, the
cells were starved in a medium without fetal bovine
serum overnight, and then 1 × 10
5 cells resuspended in
0.1 ml serum-free medium were added to the upper
chamber and RPMI-1640 containing 20% fetal bovine
serum was added to the lower chamber as a chemoat-
tractant. For the invasion assay, the inserts were pre-
coated with extracellular Matrigel (BD Biosciences, Bed-
ford, MA). To measure the effect of miR-133a mimic on
MDA-MB-231 invasion and migration potential, the
cells in the upper chamber were cultured for 28 h, while
20 h incubation for miR-133a ASO on MCF-7 cells.
Invaded or migrated cells were fixed and stained with
0.1% crystal violet. Five low-magnification areas (× 100)
were randomly selected and counted for the cell num-
bers. All experiments were performed in triplicate.
Western blot analysis
Seventy-two hours after gene transfection, the cells were
washed twice with cold PBS and total cellular protein
was extracted using a modified radioimmunoprecipita-
tion assay (RIPA) lysis buffer (50 mM Tris-HCl, pH 7.4;
1% NP-40; 0.25% Na-deoxycholate; 150 mM NaCl; 1
mM EDTA; 1 mM PMSF; Aprotinin, leupeptin, pepsta-
tin: 1 μg/ml each; 1 mM Na3VO4; 1 mM NaF). The pro-
tein concentration was then determined by a protein
assay kit (Bio-Rad) and equal amounts of protein lysates
(50 μg) were separated by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
then electrotransferred to the nitrocellulose membrane
(GE Healthcare, Arlington Heights, IL). For Western
blotting, the membranes were blocked with 5% defatted
milk and incubated with primary antibodies at 4°C over-
night. In the next day, the membranes were washed
with PBS and then incubated with peroxidase-conju-
gated secondary antibodies (Santa Cruz Biotechnology,
S a n t aC r u z ,C A ) .T h ep r o t e i nb a n d sw e r ed e v e l o p e d
with chemiluminescence (ECL) reagents (Pierce). The
antibodies were anti-FSCN1 (diluted at 1:1000; Santa
Cruz Biotechnologies), anti-beta-actin (diluted at 1:1000;
Santa Cruz Biotechnologies).
Luciferase reporter assay
A dual-luciferase reporter vector psiCHECK2 (Promega)
was used to generate luciferase reporter constructs. The
3’-untranslated region (UTR) of human FSCN1 was
amplified from human genomic DNA with primers of
5’-ATGATTCTCGAGCCTCGCTCTGGGAGTACTA-
GGG-3’ (sense) and 5’-TATATATGCGGCCGCTGG-
GGCTGCAGACTGAGTTATT-3’ (antisense), and
inserted into the XhoI-NotI restriction sites in the 3’-
UTR of the hRluc gene in psiCHECK2 vector. MCF-7
cells were grown in 24-well plates and cotransfected
with 0.2 μgo fp s i C H E C K 2 - F S C N 13 ’UTR or psi-
CHECK2 control vector and 20 pmol miR-133a mimic
or its negative control (GenePharma) by using Lipofec-
tamine 2000. Each transfection was performed in tripli-
cate and Luciferase activity was assessed 48 h after
transfection using the Dual-Luciferase reporter assay
system (Promega). Firefly luciferase activity was normal-
ized to Renilla luciferase activity accordingly.
Bioinformatical and statistical analyses
We performed bioinformatical analysis using the
miRNA database TargetScan [32] (release 5.1, http://
www.targetscan.org) to predict miR-133a target genes.
Data were shown as means ± standard deviation (SD).
All statistical analyses were performed using the SPSS
13.0 software. Differences/correlations between groups
were compared using Pearson chi-square test for quali-
tative variables and Student t test for continuous vari-
ables. Patient relapse-free survival (RFS) and overall
survival (OS) rates was analyzed using the Kaplan-Meier
method and compared by log-rank analysis. P-value <
0.05 was considered statistically significant.
Results
Expression of miR-133a in breast tissue specimens and
breast cell lines
In this study, we first assessed expression levels of miR-
133a in 34 normal, 26 benign, and 90 cancerous tissue
samples using in situ hybridization. Our data showed
that miR-133a was predominantly expressed in luminal
epithelial cells in both ductal and lobular structures in
benign and normal breast specimens. In contrast, miR-
133a expression was significantly lower in breast cancer
tissues than in benign and normal tissues (P < 0.05; Fig-
ure 1 and Table 1). We further verified miR-133a
expression in fresh breast tissue specimens using qRT-
PCR and the data confirmed our in situ hybridization
data, i.e., miR-133a expression level was significantly
lower in breast cancer compared with benign breast dis-
ease (P < 0.01; Figure 1D). Furthermore, we chose one
normal human mammary epithelial cell line HMEC and
5 breast cancer cell lines (ZR75-1, SKBR3, T47D, MCF-
7 and MDA-MB-231) to analyze the expression of miR-
133a using qRT-PCR. We found that miR-133a expres-
sion was significantly lower in breast cancer cell lines
than that of the normal HMEC cells (Figure 1E).
After that, we associated miR-133a expression with
the corresponding clinicopathological data from the
breast cancer patients. We observed that loss expression
of miR-133a was correlated to tumor lymph nodes
metastasis (P = 0.023) and high clinical stages (P =
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133a expression and patient’sa g e ,t u m o rs i z e ,t u m o r
grade, c-erbB-2 overexpression, or estrogen receptor
and progesterone receptor status (Table 2).
Association of miR-133a expression with survival of
breast cancer patients
Next, we associated miR-133a expression with overall
survival (OS) and relapse-free survival (RFS) of breast
cancer patients using Kaplan-Meier survival analyses. As
shown in Figure 1F, patients whose primary tumors did
not express miR-133a (n = 66) had a mean RFS of 45.5
months (at a 50% 5-year RFS rate), whereas patients
with tumors expressing miR-133a (n = 24) had a mean
RFS time of 56.6 months (at a 75% 5-year RFS rate, P =
0.040). However, no unequivocal significant association
of miR-133a with OS was found (P = 0.059, data not
shown). Among the patients without tumor lymph node
metatastasis, the mean RFS miR-133a expression was
higher than that of patients without miR-133a expres-
sion, but it did not reach statistical significance (92.3%
and 81.3%, P > 0.05).
Effect of miR-133a on breast cancer cell growth
Next, we chose MCF-7 cell line as model for the follow-
ing gain-of-function and loss-of-function analysis. To
evaluate the effect on cell proliferation, MCF-7 cells were
transiently transfection of miR-133a mimic or miR-133a
Figure 1 Expression of miR-133a in breast tissue specimens and cell lines. A. Strongly positive expression of miR-133a in tissues of breast
benign disease. Magnification: ×200. B. Strongly positive expression of miR-133a in an adjacent normal breast tissue. Magnification: ×200. C.
Weakly positive expression of miR-133a in an invasive ductal carcinoma. Magnification: ×200. D. Fresh tissue samples from patients with breast
cancer or benign breast diseases were obtained from the surgery room. Total miRNA was extracted from the tissues and subjected to qRT-PCR
analysis. E. Expression of miR-133a and FSCN1 in breast cancer cell lines: Breast cell lines were grown in monolayer for 3-5 days, and miRNA and
total RNA was extracted and subjected to qRT-PCR analyses. F. Association of miR-133a expression with relapse-free survival of the patients with
breast cancer.
Table 1 Expression of miR-133a in adjacent normal,
benign, and cancerous breast tissues
miR-133a expression, n (%)
No. Negative Positive
Breast cancer 90 66 (73.3) 24 (26.7)*
Benign breast disease 26 12 (46.2) 14 (53.8)
Adjacent normal 34 19 (55.9) 15 (44.1)
*P < 0.05
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fected MCF-7 cells showed a time-dependent reduction
of cell proliferation, i.e., rates of growth inhibition were
0.8%, 8.3%, 8.8% and 18.7% for 60 h, 84 h, 108 h, and 132
h after gene transfection, respectively (P <0 . 0 5 ,F i g u r e
2A). In contrast, cells transfected with miR-133a ASO
revealed an increased trend of growth rates compared to
the ASO NC transfection, although the difference did not
reach significance (P > 0.05, Figure 2B).
Effects of miR-133a on breast cancer cell migration and
invasion
The potential impact of miR-133a on cell migration and
invasion were assessed using transwell migration and
invasion assays. After MDA-MB-231 and MCF-7 cells
were selected for expression and knockdown of miR-
133a using transient gene transfection, the transwell
assay data showed that miR-133a knockdown resulted in
induction of MCF-7 cell migration (P < 0.05) and inva-
sion rate (P < 0.01) compared with the control cells
(Figure 2C). In contrast, ectopic expression of miR-133a
in MDA-MB-231 cells resulted in significant reduction
of cell migration and invasion (both P <0 . 0 1 ) .I na d d i -
tion, the wound healing assay showed that MCF-7 cells
with miR-133a knockdown enhanced the scratch
wounds closed compared with the controls (P < 0.05,
Figure 2D).
FSCN1 is the target gene of miR-133a
After that, we performed bioinformatical analyses to
search for miR-133a targeting genes using the TargetS-
can [32] database and found that FSCN1 is one of them.
Based on the role of FSCN1 in promoting breast cancer
progression [22,33,34] and a target gene of miR-133a in
esophageal squamous cell cancer and bladder cancer
[35,36] as well as identification of one potential binding
sites of miR-133a in the FSCN1 3’-UTR (Figure 3A), we
first transfected miR-133a mimic into MCF-7 cells and
assay FSCN1 mRNA levels in these cells. We found that
miR-133a mimic significantly reduced FSCN1 mRNA
levels to 56% compared to the controls (P < 0.01; Figure
3 B ) .T h es a m ei st r u ef o rF S C N 1p r o t e i nl e v e l s( F i g u r e
3C). Furthermore, luciferase assay demonstrated that
miR-133a did bind to FSCN1 3’-UTR site (Figure 3D).
Next, to further explore whether the FSCN1 protein is
required for miR-133a-mediated changes in breast can-
cer cell migration and invasion, we utilized FSCN1
siRNA to knockdown of FSCN1 expression and per-
formed the transwell assays. We found that co-transfec-
tion of FSCN1 siRNA and miR-133a ASO significantly
abrogated miR-133a ASO-induced MCF-7 cells migra-
tion and invasion capacity (Figure 3E).
Discussion and conclusions
Although tumor invasion and metastasis is the main
cause of mortality in patients with solid cancer, our
understanding of its molecular and cellular mechanisms
is still limited. Discovery of biomarkers to monitor
tumor invasion and metastasis for application in clinical
practice could to a large extent help clinicians to effec-
tively control tumor metastasis, to determine the risk of
recurrence and to predict patient survival. The common
methods for miRNA expression analysis were Northern
blot, real-time PCR, microarray-based profiling and
bead-based technologies in either tissue specimens or
blood samples. However, these techniques are inevitably
confounded by the heterogeneity of the bio-specimens
and thus could not determine the miRNAs expression at
the diverse tissue, cell and subcellular origin and level.
To this end, we recently utilized in situ hybrization
approach to screen the miRNAs expression in clinical
Table 2 Association of miR-133a expression with
clinicopathological parameters from breast cancer
patients
Parameter No. MiR-133a
expression, n (%)
P-value
Age (years)
≤ 35 6 0 (0) 0.162
35-55 48 16 (33.3)
> 55 36 8 (22.2)
Tumor size (cm)
≤ 2 4 2 (20.0) 0.523
2-5 68 18 (26.5)
> 5 18 4 (22.2)
Lymph node metastases
0 29 13 (44.8) 0.023
1-3 33 7(21.2)
> 3 28 4 (14.3)
Tumor grade
I 4 1 (25.0) 0.153
II 57 19 (33.3)
III 29 4 (13.8)
Tumor stage
I 0 0 (0) 0.021
II 50 19(38.0)
III 36 4 (11.1)
IV 4 1(25.0)
Estrogen receptor
- 57 15 (26.3) 0.921
+ 33 9 (27.3)
Progesterone receptor
- 56 13 (23.2) 0.705
+ 34 11 (32.4)
c-erbB-2 expression
Low 62 14 (22.6) 0.192
High 28 10(35.7)
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and found several miRNAs, including miR-133a, was
aberrant expressed in breast cancer [10,28]. In the cur-
rent study, we further confirmed that miR-133a expres-
sion was significantly downregulated in breast cancer
tissue samples and cell lines, and that loss of miR-133a
expression was associated with lymph node metastasis,
high clinical stages and shorter RFS of the patients with
breast cancer. Moreover, our in vitro data demonstrated
that miR-133a negatively regulated the invasion and
migration potential of breast cancer cells. Taken alto-
gether, our current data indicate that miR-133a may
play a role in breast cancer progression and that detec-
tion of miR-133a could be further evaluated as a bio-
marker for prediction of survival of breast cancer.
Recent studies have reported altered expression of
miR-133a in several human cancers including esopha-
geal squamous cell carcinoma [35], bladder [36], ileal
carcinoid [37] and rhabdomyosarcoma [38]. Ectopic
expression of miR-133a significantly inhibited invasion
capacity of various human cancer cell lines [35,36]. In
breast cancer, miR-133a was found to be reduced by a
microarray-based analysis [39]. These previous studies
are consistent with our current data, suggesting that
miR-133a does play a role as a tumor suppressor gene
in regulation of cancer development and progression.
To understand the mechanisms by which miR-133a
suppresses tumor cell invasion and metastasis in breast
cancer, we identified FSCN1 as one of potentially miR-
133a targeting genes using bioinformatic analyses.
Figure 2 Regulation of breast cancer cell growth, invasion and migration by miR-133a. A. MCF-7 cells were grown and transiently
transfected with miR-133a mimic or negative control, and cell proliferation was then assessed afterwards. The experiments were performed in
triplicate and repeated thrice. B. MCF-7 cells were grown and transiently transfected with miR-133a ASO or negative control, and cell
proliferation was assessed afterwards. The experiments were performed in triplicate and repeated thrice. C. Transwell migration and Matrigel
invasion assays. MDA-MB-231 and MCF-7 cells were grown and transiently transfected with miR-133a mimic or miR-133a ASO for 2 days and
subjected to migration and invasion assays. Representative photographs (upper) and quantification (lower) are shown. Magnification: × 200. D.
Wound healing assay. Cells were transfected with ASO NC or miR-133a ASO for 72 h. Images were taken at 0, 24, and 48 h. Quantification of cell
motility by measuring the distance between the invading front of cells in three random selected microscopic fields for each condition and time
point. The degree of motility is expressed as percent of wound closure as compared with the zero time point. Magnification: × 100. * P < 0.05;
** P < 0.01.
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Page 7 of 10Figure 3 FSCN1 is the target gene of miR-133a in breast cancer cells. A. Putative conserved target site in the FSCN1 3’UTR was identified
with the TargetScan database: The conserved 7-bp seed sequence of miR-133a is aligned to FSCN1 mRNA. B. QRT-PCR analysis of FSCN1 mRNA
expression. Breast cancer MCF-7 cells were grown and transiently transfected with miR-133a mimic and then subjected to RNA extraction and
qRT-PCR analysis. C. Western blot analysis of FSCN1 protein expression. MCF-7 cells were grown and transfected with miR-133a mimic or
negative control. Total cellular protein was isolated and subjected to Western blot analysis of FSCN1 expression. ß-actin was used as an internal
control. D. Luciferase reporter assay. MCF-7 cells were transfected with a reporter vector psiCHECK2-FSCN1 3’UTR or psiCHECK2 control vector
and miR-133a mimic or negative control. Each transfection was carried out in triplicate. Luciferase assay was performed 48 h after gene
transfection. Firefly luciferase activity was normalized to Renilla luciferase activity. E. Transwell migration and matrigel invasion assays. MCF-7 cells
were grown and transiently transfected with miR-133a ASO, miR-133a ASO plus FSCN1 siRNA, or scrambled sequence oligonucleotides as
negative control for 2 days and subjected to migration and invasion assays. Magnification: ×200.
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Page 8 of 10FSCN1, an actin-binding protein, is essential for actin-
based motility-structures formation [19], such as micro-
spikes, lamellipodia and filopodia. FSCN1 is usually not
expressed in normal epithelial cells, but is overexpressed
in many kinds of tumors [22-27]. Increasing evidence
has demonstrated a link between overexpression of
FSCN1 and increased tumor cell motility and invasive-
ness [35,36,40]. In a previous study, overexpression of
FSCN1 in nasopharyngeal carcinoma was associated
with lymphatic metastasis and knockdown of endogen-
ous FSCN1 expression in nasopharyngeal carcinoma cell
lines using siRNA technique greatly reduced cell inva-
sive ability and decreased filopodia formation [40].
Other studies showed that decreased FSCN1 expression
through FSCN1 siRNA also weakened invasiveness of
esophageal squamous cell carcinoma and bladder cancer
cells [35,36]. On the other hand, elevated expression of
FSCN1 in breast cancer MDA-MB-435 cell line was
greatly enhanced cell dynamics and motility and
increased microspike and filopodia formation [34].
These data prompt us to investigate the potential rela-
tionship between FSCN1 and miR-133a in breast cancer.
Indeed, we found that breast cancer cells transfected
with miR-133a mimics had dramatically lowered levels
of FSCN1 mRNA and protein compared with the con-
trol cells. The luciferase reporter assay confirmed that
FSCN1 is a direct target of miR-133a in breast cancer
cells. Moreover, we further demonstrated that FSCN1
was required for miR-133a-mediated changes in breast
cancer migration and invasion capacity. Consistent with
our data, recent studies in other types of malignances
(such as esophageal squamous cell carcinoma and blad-
der cancer) also showed that miR-133a could directly
bind to FSCN1 gene [35,36].
In this study, we confirmed the downregulation of miR-
133a in breast cancer tissues and demonstrated association
of the lost miR-133a expression with lymph node metasta-
sis, high clinical stages, and shorter survival of these breast
cancer patients. We also explored the potential target of
miR-133a to be FSCN1 in vitro. However, our current ex
vivo data was not supported by any in vivo data, such as a
xenograft model to confirm whether restoration of miR-
133a expression could reduce breast cancer cell metastasis
in vivo. We recognized this limitation but our arguments
are i). Such an animal experiment requires stable gene
transfection, which may generate selection bias for resis-
tant cell sublines, unless to use an inducible vector; ii).
Addition of xenograft assay will not mechanistically
answer the question of the role of mir-133a in silence of
FSCN1 in breast cancer; and iii). the conclusion of our
current ex vivo data is clear and justified, although there is
a need to be further verified in different patient popula-
tions before use of miR-133a as a biomarker for predica-
tion of breast cancer invasion and metastasis in clinic.
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